These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

431 related items for PubMed ID: 32086878

  • 1. Changes in kidney function among men having sex with men starting on demand tenofovir disoproxil fumarate - emtricitabine for HIV pre-exposure prophylaxis.
    Liegeon G, Antoni G, Pialoux G, Capitant C, Cotte L, Charreau I, Tremblay C, Cua E, Senneville E, Raffi F, Meyer L, Molina JM, ANRS-IPERGAY study group.
    J Int AIDS Soc; 2020 Feb; 23(2):e25420. PubMed ID: 32086878
    [Abstract] [Full Text] [Related]

  • 2. Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial.
    Mugwanya KK, Wyatt C, Celum C, Donnell D, Mugo NR, Tappero J, Kiarie J, Ronald A, Baeten JM, Partners PrEP Study Team.
    JAMA Intern Med; 2015 Feb; 175(2):246-54. PubMed ID: 25531343
    [Abstract] [Full Text] [Related]

  • 3. Reversibility of Glomerular Renal Function Decline in HIV-Uninfected Men and Women Discontinuing Emtricitabine-Tenofovir Disoproxil Fumarate Pre-Exposure Prophylaxis.
    Mugwanya KK, Wyatt C, Celum C, Donnell D, Kiarie J, Ronald A, Baeten JM, Partners PrEP Study Team.
    J Acquir Immune Defic Syndr; 2016 Apr 01; 71(4):374-80. PubMed ID: 26914909
    [Abstract] [Full Text] [Related]

  • 4. Kidney function and daily emtricitabine/tenofovir disoproxil fumarate pre-exposure prophylaxis against HIV: results from the real-life multicentric demonstrative project PrEP Brazil.
    Petruccelli KCS, Baía-da-Silva DC, Val F, Valões MS, Cubas-Vega N, Silva-Neto AV, Sampaio V, Alencar A, Pecoits-Filho R, Moreira RC, Cardoso SW, Moreira RI, Leite IC, Madruga JV, Kallas EG, Alencastro PR, Hoagland B, Grinsztejn B, Santos VGV, Lacerda MVG.
    AIDS Res Ther; 2022 Feb 24; 19(1):12. PubMed ID: 35209929
    [Abstract] [Full Text] [Related]

  • 5. On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a post-hoc analysis of the ANRS IPERGAY trial.
    Antoni G, Tremblay C, Delaugerre C, Charreau I, Cua E, Rojas Castro D, Raffi F, Chas J, Huleux T, Spire B, Capitant C, Cotte L, Meyer L, Molina JM, ANRS IPERGAY study group.
    Lancet HIV; 2020 Feb 24; 7(2):e113-e120. PubMed ID: 31784343
    [Abstract] [Full Text] [Related]

  • 6. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study.
    Molina JM, Charreau I, Spire B, Cotte L, Chas J, Capitant C, Tremblay C, Rojas-Castro D, Cua E, Pasquet A, Bernaud C, Pintado C, Delaugerre C, Sagaon-Teyssier L, Mestre SL, Chidiac C, Pialoux G, Ponscarme D, Fonsart J, Thompson D, Wainberg MA, Doré V, Meyer L, ANRS IPERGAY Study Group.
    Lancet HIV; 2017 Sep 24; 4(9):e402-e410. PubMed ID: 28747274
    [Abstract] [Full Text] [Related]

  • 7. Transgender women on oral HIV pre-exposure prophylaxis have significantly lower tenofovir and emtricitabine concentrations when also taking oestrogen when compared to cisgender men.
    Shieh E, Marzinke MA, Fuchs EJ, Hamlin A, Bakshi R, Aung W, Breakey J, Poteat T, Brown T, Bumpus NN, Hendrix CW.
    J Int AIDS Soc; 2019 Nov 24; 22(11):e25405. PubMed ID: 31692269
    [Abstract] [Full Text] [Related]

  • 8. Pre-exposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine and Kidney Tubular Dysfunction in HIV-Uninfected Individuals.
    Jotwani V, Scherzer R, Glidden DV, Mehrotra M, Defechereux P, Liu A, Gandhi M, Bennett M, Coca SG, Parikh CR, Grant RM, Shlipak MG.
    J Acquir Immune Defic Syndr; 2018 Jun 01; 78(2):169-174. PubMed ID: 29767638
    [Abstract] [Full Text] [Related]

  • 9. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
    Mayer KH, Molina JM, Thompson MA, Anderson PL, Mounzer KC, De Wet JJ, DeJesus E, Jessen H, Grant RM, Ruane PJ, Wong P, Ebrahimi R, Zhong L, Mathias A, Callebaut C, Collins SE, Das M, McCallister S, Brainard DM, Brinson C, Clarke A, Coll P, Post FA, Hare CB.
    Lancet; 2020 Jul 25; 396(10246):239-254. PubMed ID: 32711800
    [Abstract] [Full Text] [Related]

  • 10. Changes in Kidney Function Associated With Daily Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Preexposure Prophylaxis Use in the United States Demonstration Project.
    Tang EC, Vittinghoff E, Anderson PL, Cohen SE, Doblecki-Lewis S, Bacon O, Coleman ME, Buchbinder SP, Chege W, Kolber MA, Elion R, Shlipak M, Liu AY.
    J Acquir Immune Defic Syndr; 2018 Feb 01; 77(2):193-198. PubMed ID: 28991887
    [Abstract] [Full Text] [Related]

  • 11. Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure Prophylaxis.
    Havens PL, Stephensen CB, Van Loan MD, Schuster GU, Woodhouse LR, Flynn PM, Gordon CM, Pan CG, Rutledge B, Liu N, Wilson CM, Hazra R, Hosek SG, Anderson PL, Seifert SM, Kapogiannis BG, Mulligan K, Adolescent Medicine Trials Network for HIV/AIDS Interventions 117 study team.
    Clin Infect Dis; 2017 Feb 01; 64(3):317-325. PubMed ID: 28013265
    [Abstract] [Full Text] [Related]

  • 12. HIV-1 infection kinetics, drug resistance, and long-term safety of pre-exposure prophylaxis with emtricitabine plus tenofovir alafenamide (DISCOVER): week 144 open-label extension of a randomised, controlled, phase 3 trial.
    Wohl DA, Spinner CD, Flamm J, Hare CB, Doblecki-Lewis S, Ruane PJ, Molina JM, Mills A, Brinson C, Ramgopal M, Clarke A, Crofoot G, Martorell C, Carter C, Cox S, Hojilla JC, Shao Y, Das M, Kintu A, Baeten JM, Grant RM, Mounzer K, Mayer K.
    Lancet HIV; 2024 Aug 01; 11(8):e508-e521. PubMed ID: 39008999
    [Abstract] [Full Text] [Related]

  • 13. Liver and renal safety of tenofovir disoproxil fumarate in combination with emtricitabine among African women in a pre-exposure prophylaxis trial.
    Mandala J, Nanda K, Wang M, De Baetselier I, Deese J, Lombaard J, Owino F, Malahleha M, Manongi R, Taylor D, Van Damme L.
    BMC Pharmacol Toxicol; 2014 Dec 24; 15():77. PubMed ID: 25539648
    [Abstract] [Full Text] [Related]

  • 14. Emtricitabine/tenofovir disoproxil fumarate: a review of its use in HIV-1 pre-exposure prophylaxis.
    Plosker GL.
    Drugs; 2013 Mar 24; 73(3):279-91. PubMed ID: 23444256
    [Abstract] [Full Text] [Related]

  • 15. Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial.
    Mulligan K, Glidden DV, Anderson PL, Liu A, McMahan V, Gonzales P, Ramirez-Cardich ME, Namwongprom S, Chodacki P, de Mendonca LM, Wang F, Lama JR, Chariyalertsak S, Guanira JV, Buchbinder S, Bekker LG, Schechter M, Veloso VG, Grant RM, Preexposure Prophylaxis Initiative Study Team.
    Clin Infect Dis; 2015 Aug 15; 61(4):572-80. PubMed ID: 25908682
    [Abstract] [Full Text] [Related]

  • 16. On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection.
    Molina JM, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, Tremblay C, Le Gall JM, Cua E, Pasquet A, Raffi F, Pintado C, Chidiac C, Chas J, Charbonneau P, Delaugerre C, Suzan-Monti M, Loze B, Fonsart J, Peytavin G, Cheret A, Timsit J, Girard G, Lorente N, Préau M, Rooney JF, Wainberg MA, Thompson D, Rozenbaum W, Doré V, Marchand L, Simon MC, Etien N, Aboulker JP, Meyer L, Delfraissy JF, ANRS IPERGAY Study Group.
    N Engl J Med; 2015 Dec 03; 373(23):2237-46. PubMed ID: 26624850
    [Abstract] [Full Text] [Related]

  • 17. Daily and on-demand HIV pre-exposure prophylaxis with emtricitabine and tenofovir disoproxil (ANRS PREVENIR): a prospective observational cohort study.
    Molina JM, Ghosn J, Assoumou L, Delaugerre C, Algarte-Genin M, Pialoux G, Katlama C, Slama L, Liegeon G, Beniguel L, Ohayon M, Mouhim H, Goldwirt L, Spire B, Loze B, Surgers L, Pavie J, Lourenco J, Ben-Mechlia M, Le Mestre S, Rojas-Castro D, Costagliola D, ANRS PREVENIR Study Group.
    Lancet HIV; 2022 Aug 03; 9(8):e554-e562. PubMed ID: 35772417
    [Abstract] [Full Text] [Related]

  • 18. Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Ogbuagu O, Ruane PJ, Podzamczer D, Salazar LC, Henry K, Asmuth DM, Wohl D, Gilson R, Shao Y, Ebrahimi R, Cox S, Kintu A, Carter C, Das M, Baeten JM, Brainard DM, Whitlock G, Brunetta JM, Kronborg G, Spinner CD, DISCOVER study team.
    Lancet HIV; 2021 Jul 03; 8(7):e397-e407. PubMed ID: 34197772
    [Abstract] [Full Text] [Related]

  • 19. Low Risk of Proximal Tubular Dysfunction Associated With Emtricitabine-Tenofovir Disoproxil Fumarate Preexposure Prophylaxis in Men and Women.
    Mugwanya K, Baeten J, Celum C, Donnell D, Nickolas T, Mugo N, Branch A, Tappero J, Kiarie J, Ronald A, Yin M, Wyatt C, Partners PrEP Study Team.
    J Infect Dis; 2016 Oct 01; 214(7):1050-7. PubMed ID: 27029778
    [Abstract] [Full Text] [Related]

  • 20. PrEP Demonstration Project Showed Superior Adherence with Tenofovir Alafenamide/Emtricitabine Compared to Tenofovir Disoproxil Fumarate/Emtricitabine in a Sample of Partnered Sexual Minority Men.
    Robles G, Sauermilch D, Gandhi M, Starks TJ.
    AIDS Behav; 2021 Apr 01; 25(4):1299-1305. PubMed ID: 33206262
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.